- Home
- JMM vs ATNM Comparison
JMM vs ATNM Comparison
Compare JMM & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JMM
- ATNM
- Stock Information
- Founded
- JMM 1988
- ATNM 2000
- Country
- JMM United States
- ATNM United States
- Employees
- JMM N/A
- ATNM N/A
- Industry
- JMM Trusts Except Educational Religious and Charitable
- ATNM Biotechnology: Pharmaceutical Preparations
- Sector
- JMM Finance
- ATNM Health Care
- Exchange
- JMM Nasdaq
- ATNM Nasdaq
- Market Cap
- JMM 56.8M
- ATNM 56.5M
- IPO Year
- JMM N/A
- ATNM N/A
- Fundamental
- Price
- JMM $5.98
- ATNM $1.40
- Analyst Decision
- JMM
- ATNM Strong Buy
- Analyst Count
- JMM 0
- ATNM 4
- Target Price
- JMM N/A
- ATNM $8.75
- AVG Volume (30 Days)
- JMM 16.1K
- ATNM 342.1K
- Earning Date
- JMM 01-01-0001
- ATNM 11-14-2024
- Dividend Yield
- JMM 5.44%
- ATNM N/A
- EPS Growth
- JMM N/A
- ATNM N/A
- EPS
- JMM N/A
- ATNM N/A
- Revenue
- JMM N/A
- ATNM $81,000.00
- Revenue This Year
- JMM N/A
- ATNM $138.42
- Revenue Next Year
- JMM N/A
- ATNM $19,479.88
- P/E Ratio
- JMM N/A
- ATNM N/A
- Revenue Growth
- JMM N/A
- ATNM N/A
- 52 Week Low
- JMM $5.29
- ATNM $1.10
- 52 Week High
- JMM $6.10
- ATNM $10.24
- Technical
- Relative Strength Index (RSI)
- JMM 43.26
- ATNM 56.03
- Support Level
- JMM $5.97
- ATNM $1.18
- Resistance Level
- JMM $6.14
- ATNM $1.48
- Average True Range (ATR)
- JMM 0.08
- ATNM 0.10
- MACD
- JMM -0.00
- ATNM 0.01
- Stochastic Oscillator
- JMM 30.43
- ATNM 75.00
About JMM Nuveen Multi-Market Income Fund (MA)
Nuveen Multi-Market Income Fund is a United States-based closed-end management investment company. The investment objective of the company is to provide high monthly income consistent with prudent risk to capital. The fund predominantly invests in debt securities including, but not limited to residential and commercial mortgage-backed securities, asset-backed securities, corporate debt obligations, convertible debt securities, U.S. government securities, and other such fixed income instruments. It may also invest in preferred stocks.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.